Fresenius SE & Co. KGaA

 

Medicine & Research - 2007

21.12.2007 Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab® for the treatment of malignant ascites
PDF Text as PDF-file
07.11.2007 Fresenius Medical Care Announces Continued Positive Data from CARE-2 Database
PDF Text as PDF-file
17.07.2007 Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
PDF Text as PDF-file
25.06.2007 Confirmed by new study: high-flux dialyzers improve survival of dialysis patients
PDF Text as PDF-file
22.03.2007 Phase II/III pivotal study with trifunctional antibody removab® shows encouraging results in malignant ascites from various cancers
PDF Text as PDF-file
01.02.2007 Fresenius Medical Care and Amgen Establish a Joint Research Program in Europe
PDF Text as PDF-file
23.01.2007 Fresenius Medical Care Announces FDA Submission of New Drug Application for PhosLo
PDF Text as PDF-file
16.01.2007 Fresenius Medical Care expands dialyzer production capacity at St. Wendel (Germany)
PDF Text as PDF-file


Home > Press > Press Releases > Medicine & Research > 2007